lomefloxacin has been researched along with curcumin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, P; Chen, C; Hu, K; Li, T; Liu, W; Ma, Q; Pan, W; Peng, K; Sang, Z; Yu, L; Zhang, X | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Ding, Y; Lan, JS; Liu, J; Liu, Y; Miao, ZY; Xie, SS; Yang, J; Zhang, T | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, HL; Yang, XL | 1 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Chen, L; Lei, Z; Sun, J; Sun, X; Wang, Y; Yue, S | 1 |
7 other study(ies) available for lomefloxacin and curcumin
| Article | Year |
|---|---|
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alkanes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Drug Evaluation, Preclinical; Ethylamines; Humans; Hydrogen Peroxide; Neuroprotective Agents; PC12 Cells; Rats | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Donepezil; Drug Design; Electrophorus; Humans; Indans; Mice; Molecular Docking Simulation; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Piperidines; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Brain Barrier; Chromones; Copper; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Protein Structure, Tertiary; Rats; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Rats | 2022 |